Roberto Flores-Peña
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Roberto Flores-Peña has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Hugo Christian Monroy-Ramirez
Universidad de Guadalajara
3 shared publications - Juan Armendariz-Borunda
Universidad de Guadalajara
3 shared publications - Fernando Caloca-Camarena
Programa de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico; Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico
2 shared publications - Jorge Alejandro Salto-Sevilla
Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, México
2 shared publications - Marina Galicia-Moreno
Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, México
2 shared publications - Scarlet Arceo-Orozco
Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, México
2 shared publications
Latest Publications
- 23 May 2026
- Published by Elsevier in Cellular Signalling
- Vol. 145, 112614
N-acetylcysteine–induced transcriptomic reprogramming regulates Nrf2-mediated signaling and redox homeostasis in experimental hepatocellular carcinoma
- 23 May 2026
- Published by Elsevier in Cellular Signalling
- Vol. 145, 112614
N-acetylcysteine–induced transcriptomic reprogramming regulates Nrf2-mediated signaling and redox homeostasis in experimental hepatocellular carcinoma
- Open Access
- 10 August 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (8) , 979
Naringin and Naringenin in Liver Health: A Review of Molecular and Epigenetic Mechanisms and Emerging Therapeutic Strategies
Liver diseases have become a significant global health concern, driving increased interest in naturally occurring compounds as adjunctive treatments for managing these conditions. Flavonoids, a class of natural polyphenols found in plants and fruits, offer a broad spectrum of potential health benefits due to their applications in nutraceuticals, pharmaceuticals, and cosmetics. Among them, naringin (NARI) and naringenin (NAR), which are abundant in citrus fruits, have attracted considerable attention. Numerous studies have investigated the therapeutic effects of NARI and NAR across different stages of liver disease. This review highlights recent research on the impact of these flavonoids in alcohol-related liver disease and metabolic dysfunction-associated fatty liver disease (MASLD). It also explores the molecular mechanisms and epigenetic modifications through which NARI and NAR contribute to preventing liver disease progression. Finally, this work discusses recent progresses and future perspectives, emphasizing the role of innovative nanocarriers, nanoparticles, and drug delivery strategies in enhancing the efficacy and bioavailability of these promising compounds to improve liver health.
- 10 August 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (8) , 979
Open AccessNaringin and Naringenin in Liver Health: A Review of Molecular and Epigenetic Mechanisms and Emerging Therapeutic Strategies
Liver diseases have become a significant global health concern, driving increased interest in naturally occurring compounds as adjunctive treatments for managing these conditions. Flavonoids, a class of natural polyphenols found in plants and fruits, offer a broad spectrum of potential health benefits due to their applications in nutraceuticals, pharmaceuticals, and cosmetics. Among them, naringin (NARI) and naringenin (NAR), which are abundant in citrus fruits, have attracted considerable attention. Numerous studies have investigated the therapeutic effects of NARI and NAR across different stages of liver disease. This review highlights recent research on the impact of these flavonoids in alcohol-related liver disease and metabolic dysfunction-associated fatty liver disease (MASLD). It also explores the molecular mechanisms and epigenetic modifications through which NARI and NAR contribute to preventing liver disease progression. Finally, this work discusses recent progresses and future perspectives, emphasizing the role of innovative nanocarriers, nanoparticles, and drug delivery strategies in enhancing the efficacy and bioavailability of these promising compounds to improve liver health.
- Open Access
- 26 May 2025
- Published by Springer Nature in Journal of Materials Science: Materials in Engineering
- Vol. 20 (1) , 1-22
Cerium oxide nanoparticles: a promising nanotherapy approach for chronic degenerative diseases
Oxidative stress is a process caused by excess-free radicals and reactive oxygen species (ROS), which contribute to the onset and progression of various chronic degenerative diseases. Consequently, interest has grown in studying natural and synthetic antioxidant compounds that restore normal ROS metabolism, alleviating the damage in affected tissues. Despite the above, several preclinical and clinical studies evaluating these therapies have shown some contradictory results since sometimes the use of these molecules has not shown the desired therapeutic efficacy, or in some cases, the use of these antioxidants has been related to the appearance of harmful effects due to their lack of specificity, to the associated adverse effects, in addition to the fact that some ROS are essential for normal physiological functions. On the other hand, nanotechnology is one of the most widely used technological advances in the drug industry. Targeted delivery of active ingredients combines knowledge of pharmacology, pharmaceutical development, polymer sciences, conjugate chemistry, and molecular biology to improve the pharmacokinetics of active ingredients, decreasing their toxicity, immunogenicity, and biorecognition. Cerium oxide nanoparticles (CeO2-NPs) have emerged as a novel therapeutic alternative with high antioxidant capacity, demonstrating beneficial effects in both in vivo and in vitro studies for treating chronic degenerative disorders. CeO2-NPs are only activated when ROS levels reach a harmful threshold, which protects healthy cells from unwanted effects. Their therapeutic potential has been demonstrated in multiple fields of medicine, including oncology, neurology, ophthalmology, cardiology, and hepatology. Therefore, this review addresses the potential applications of CeO2-NPs evaluated in animal and in vitro models of chronic degenerative diseases, which help visualize and position them as an effective and safe therapeutic alternative for treating this condition.
- 26 May 2025
- Published by Springer Nature in Journal of Materials Science: Materials in Engineering
- Vol. 20 (1) , 1-22
Open AccessCerium oxide nanoparticles: a promising nanotherapy approach for chronic degenerative diseases
Oxidative stress is a process caused by excess-free radicals and reactive oxygen species (ROS), which contribute to the onset and progression of various chronic degenerative diseases. Consequently, interest has grown in studying natural and synthetic antioxidant compounds that restore normal ROS metabolism, alleviating the damage in affected tissues. Despite the above, several preclinical and clinical studies evaluating these therapies have shown some contradictory results since sometimes the use of these molecules has not shown the desired therapeutic efficacy, or in some cases, the use of these antioxidants has been related to the appearance of harmful effects due to their lack of specificity, to the associated adverse effects, in addition to the fact that some ROS are essential for normal physiological functions. On the other hand, nanotechnology is one of the most widely used technological advances in the drug industry. Targeted delivery of active ingredients combines knowledge of pharmacology, pharmaceutical development, polymer sciences, conjugate chemistry, and molecular biology to improve the pharmacokinetics of active ingredients, decreasing their toxicity, immunogenicity, and biorecognition. Cerium oxide nanoparticles (CeO2-NPs) have emerged as a novel therapeutic alternative with high antioxidant capacity, demonstrating beneficial effects in both in vivo and in vitro studies for treating chronic degenerative disorders. CeO2-NPs are only activated when ROS levels reach a harmful threshold, which protects healthy cells from unwanted effects. Their therapeutic potential has been demonstrated in multiple fields of medicine, including oncology, neurology, ophthalmology, cardiology, and hepatology. Therefore, this review addresses the potential applications of CeO2-NPs evaluated in animal and in vitro models of chronic degenerative diseases, which help visualize and position them as an effective and safe therapeutic alternative for treating this condition.